Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

China · Delayed Price · Currency is CNY

45.01

+1.21 (2.76%)

Jun 18, 2026, 3:00 PM CST

11.27% (1Y)

Market Cap	7.85B +26.4%
Revenue (ttm)	1.35B +0.9%
Net Income	274.30M +22.6%
EPS	1.58 +24.4%
Shares Out	174.35M
PE Ratio	28.48
Forward PE	n/a
Dividend	0.49 (1.09%)
Ex-Dividend Date	Jun 2, 2026

Volume	2,242,828
Open	43.13
Previous Close	43.80
Day's Range	43.00 - 46.18
52-Week Range	37.50 - 80.48
Beta	-0.00
Analysts	Buy
Price Target	43.00 (-4.47%)
Earnings Date	Aug 18, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricarace... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 1,480

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688513

Full Company Profile

Financial Performance

In 2025, SHA:688513's revenue was 1.33 billion, a decrease of -1.36% compared to the previous year's 1.35 billion. Earnings were 284.06 million, an increase of 19.24%.

Financial Statements